Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sepracor's "Product And Use" Lunesta Ad To Be "Very Visible," Company Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Sepracor's Lunesta (eszopiclone) "product and use" ad campaign will "be very visible going forward," the company said during its April 25 earnings call

You may also be interested in...



Sepracor Sees Reward In Lunesta Promotion Push

Sepracor credits its intensive marketing sales and education programs as the key to new prescription growth in the third quarter despite the recent entry of two competing sleep aids.

Sepracor Sees Reward In Lunesta Promotion Push

Sepracor credits its intensive marketing sales and education programs as the key to new prescription growth in the third quarter despite the recent entry of two competing sleep aids.

Takeda's Rozerem Will Not Be First-Line Competitor To Ambien, Sanofi Says

Rozerem (ramelteon) launch could open a new segment of sleep aid market; Sanofi-Aventis predicts the insomnia agent's different mechanism of action will prevent it from competing directly with Ambien. Company is readying launch of Ambien CR to counter increased competition.

Related Content

Topics

UsernamePublicRestriction

Register

PS062072

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel